Venmax Drugs and Pharmaceuticals Ltd (531015)
சுருக்கம்
The board meets on 12 Nov 2026 to consider the Q2 FY27 results.
நிகழ்வுகள்
- அடுத்த முடிவுகள்
- 12 நவ. 2026 (Q2 FY27)
- சமீபத்திய முடிவுகள்
- Q1 FY27, தாக்கல் செய்யப்பட்டது 7 ஆக. 2026
- இயக்குநர் குழுக் கூட்ட அறிவிப்பு
- 5 நவ. 2026
பங்குச் சந்தைத் தரவு. ஒவ்வொரு எண்ணும் அதன் சொந்தப் பக்கம் காட்டும் வடிவத்திலேயே; தேதிகள் தரவின் தேதிகள். தகவலுக்கு மட்டுமே, முதலீட்டு ஆலோசனை அல்ல.
📈 பங்கு விலை & நிகழ்வுகள்
Q2 FY27 முடிவுகள்
📅 அடுத்த நிதி முடிவுகள்: 12 நவ. 2026 (இயக்குநர் குழுக் கூட்டம்)Venmax Drugs and Pharmaceuticals Ltd-இன் இயக்குநர் குழுக் கூட்டம் 12 நவ. 2026 அன்று நடைபெறுகிறது; அதில் அதன் Q2 FY27 முடிவுகள் பரிசீலிக்கப்படும் (ஜூலை-செப்டம்பர் 2026).
In its latest reported quarter, Q1 FY27, Venmax Drugs' revenue was ₹2.5 Cr (+104.9% year on year, -37.1% on the previous quarter), and net profit ₹-0.0 Cr (against a profit a year earlier); the operating margin was 4.7%.
| Q1 FY27 (₹ கோடி) | மதிப்பு | YoY Q1 FY26-உடன் | QoQ |
|---|---|---|---|
| வருவாய் | ₹2.5 | +104.9% | -37.1% |
| செயல்பாட்டு லாபம் | ₹0.1 | +194.0% | +488.0% |
| நிகர லாபம் | ₹-0.0 | நஷ்டமாக | நஷ்டமாக |
| செயல்பாட்டு லாப வரம்பு | 4.7% | — | — |
📢 சமீபத்திய கார்ப்பரேட் அறிவிப்புகள்
Venmax Drugs and Pharmaceuticals Ltd has submitted its quarterly statement of deviation or variation under Regulation 32 for the quarter ended September 30, 2026. The company confirmed no deviation in the use of proceeds raised via fully convertible equity warrants on a preferential basis. Out of a total planned raise of ₹20.05 crore, ₹18.49 crore has been received against the conversion of 92,44,999 warrants. The statement was reviewed by the Audit Committee on November 12, 2026, with nil auditor remarks.
- Zero deviation or variation reported in preferential issue proceeds utilization for Q2 FY27 (quarter ended September 30, 2026)
- Total fundraise planned at ₹20.05 crores, of which ₹18.49 crores has been raised and received to date
- Proceeds received against the conversion of 92,44,999 share warrants
- Initial shareholder approval for the preferential issue was secured on February 6, 2025
Venmax Drugs and Pharmaceuticals reported a revenue from operations of ₹528.21 lakh (₹5.28 crore) for Q2 FY27 (quarter ended September 30, 2026), marking a sharp increase from ₹131.85 lakh in Q2 FY26 and ₹247.94 lakh in Q1 FY27. Net profit for the quarter rose to ₹12.03 lakh compared to ₹2.44 lakh in the corresponding year-ago period. For H1 FY27, revenue reached ₹776.15 lakh with net profit of ₹23.69 lakh, nearly matching full-year FY26 revenue of ₹802.49 lakh. Despite the top-line expansion, operating cash flow for H1 FY27 remained negative at ₹(471.07) lakh, largely due to working capital expansion.
- Revenue from operations jumped 300% YoY to ₹528.21 lakh in Q2 FY27 compared to ₹131.85 lakh in Q2 FY26
- Net profit reached ₹12.03 lakh in Q2 FY27 versus ₹2.44 lakh in Q2 FY26 and ₹11.66 lakh in Q1 FY27
- H1 FY27 total revenue was ₹776.15 lakh, achieving ~97% of full-year FY26 revenue (₹802.49 lakh)
- Operating cash flow remained negative at ₹(471.07) lakh in H1 FY27 due to ₹802.63 lakh outflow in other financial assets
- Share capital increased to ₹1448.39 lakh as of September 30, 2026, from ₹1158.29 lakh as of March 31, 2026
Venmax Drugs and Pharmaceuticals Ltd has scheduled a meeting of its Board of Directors on Thursday, November 12, 2026, to consider and approve unaudited financial results for the quarter ended September 30, 2026. The trading window for designated persons has been closed since October 1, 2026, and will reopen on November 14, 2026, 48 hours post-declaration. The micro-cap company currently operates with a TTM revenue of ₹9 Cr and a market cap of ₹15 Cr.
- Board meeting scheduled for November 12, 2026 at 3.00 P.M
- Agenda covers approval of Unaudited Financial Results for quarter ended September 30, 2026
- Trading window closed from October 1, 2026 to November 14, 2026
Venmax Drugs and Pharmaceuticals has issued a notice convening an NCLT-directed meeting of equity shareholders on October 24, 2026, to vote on the proposed Scheme of Amalgamation with Hatri Pharma Private Limited. The order was granted by the Hon'ble NCLT Hyderabad Bench-II on September 7, 2026. The company is micro-cap with a market capitalization of Rs 15 Cr and TTM revenue of Rs 9 Cr, making this amalgamation structurally significant depending on the unlisted entity's size. However, exact share exchange ratios and Hatri Pharma's financial metrics were not detailed in the main notice text.
- NCLT Hyderabad Bench-II directed meeting scheduled for Saturday, October 24, 2026 at 12:30 PM
- Scheme involves merger of Hatri Pharma Private Limited (Transferor) into Venmax Drugs (Transferee)
- NCLT approval order passed on September 7, 2026 under Sections 230-232 of the Companies Act, 2013
- Company trades at a market cap of Rs 15 Cr with TTM revenue of Rs 9 Cr
Venmax Drugs and Pharmaceuticals announced the outcome of its board meeting held on August 31, 2026. The board approved convening the 37th Annual General Meeting (AGM) on September 26, 2026, with the cut-off date set as September 18, 2026. Key management decisions include the redesignation of Mr. Venkata Rao Sadhanala as Managing Director for a 5-year term with an annual remuneration of ₹30 lakhs, subject to shareholder approval. Additionally, the appointments of Mrs. Padmaja Kalyani Sadhanala (Non-Executive Non-Independent Director) and Mr. Revoor Ramachandra (Independent Director) were recommended for regularization.
- 37th AGM scheduled for Saturday, September 26, 2026, via Video Conferencing.
- Mr. Venkata Rao Sadhanala redesignated as MD for 5 years (March 11, 2026 to March 10, 2031) at ₹30 lakhs p.a. remuneration.
- Cut-off date for remote e-voting finalized as Friday, September 18, 2026.
- Regularization of two Additional Directors approved, subject to shareholder consent.
Venmax Drugs and Pharmaceuticals Ltd has scheduled a Board of Directors meeting on Monday, August 31, 2026, at 4:30 PM. The agenda includes approving the Notice and Annual Report for the 37th Annual General Meeting (AGM) for FY 2025-26. Additionally, the board will consider regularizing the appointment of Additional Directors and approving a change in designation for the Whole-time Director, subject to shareholder approval. This is an administrative compliance notification with no immediate operational impact.
- Board meeting scheduled for August 31, 2026, at 4:30 PM
- Agenda to approve Notice, Directors Report, and 37th Annual Report for FY 2025-26
- Board to determine AGM date, time, venue, and e-voting cut-off dates
- Consideration of regularization of Additional Directors and designation change of Whole-time Director
Venmax Drugs and Pharmaceuticals Ltd has confirmed zero deviation in the utilization of proceeds from its ₹20.05 crore preferential issue of equity warrants. As of June 30, 2026, the company has received approximately ₹14.53 crores (comprising ₹12.69 crores from warrant conversions and ₹1.84 crores from warrant subscriptions). Of the ₹10 crores specifically allocated for working capital, the company has utilized ₹8.37 crores. This filing confirms that the capital is being deployed as per the objects approved by shareholders in February 2025.
- Total planned fundraise of ₹20.05 crores via fully convertible equity warrants on a preferential basis.
- ₹12.69 crores raised and received from investors against the conversion of 63,44,000 share warrants.
- ₹1.84 crores received against 36,81,000 share warrants as of the reporting date.
- ₹8.37 crores utilized for working capital requirements out of an original allocation of ₹10 crores.
- Audit Committee confirmed zero deviation from the objects stated in the EGM notice dated February 6, 2025.
Venmax Drugs reported a 105% YoY increase in revenue to ₹2.48 Cr for the quarter ended June 30, 2026, although revenue declined 37% sequentially from the March 2026 quarter. Net profit rose to ₹0.12 Cr from ₹0.04 Cr in the previous year's corresponding quarter. The company also approved the forfeiture of 7,80,001 partly paid-up share warrants as holders failed to pay the 75% balance amount, resulting in the company retaining ₹0.39 Cr. Despite the growth, the company remains a micro-cap with a very low promoter holding of 10.46%.
- Revenue from operations increased 105% YoY to ₹2.48 Cr from ₹1.21 Cr in June 2025.
- Net profit grew 200% YoY to ₹0.12 Cr compared to ₹0.04 Cr in the same period last year.
- Forfeited 7,80,001 convertible share warrants due to non-payment of the ₹15 per warrant balance.
- Retained ₹39,00,005 as forfeited upfront subscription money, which is approximately 4.9% of TTM revenue.
- Total assets increased slightly to ₹16.83 Cr as of June 30, 2026, from ₹16.20 Cr in March 2026.
Venmax Drugs and Pharmaceuticals has scheduled a board meeting on August 7, 2026, to approve its unaudited financial results for the quarter ended June 30, 2026. Additionally, the board will consider the forfeiture of partly paid-up share warrants, indicating that certain investors may have failed to pay the remaining balance on their warrants. This is significant for a micro-cap company with a market capitalization of only ₹17 Cr and a low promoter holding of 10.46%. Investors should monitor if the revenue momentum from March 2026 (₹3.94 Cr) continues into the new fiscal year.
- Board meeting scheduled for August 7, 2026, to approve Q1 FY27 results
- Proposal to forfeit partly paid-up share warrants will be considered
- Trading window for designated persons remains closed until August 9, 2026
- Promoter holding has declined significantly from 23.13% in Sep 2025 to 10.46% in Jun 2026
- Company reported TTM revenue of ₹8 Cr against a market cap of ₹17 Cr
Venmax Drugs and Pharmaceuticals has allotted 7,53,334 equity shares to a non-promoter investor, Dinesh Muddu Kotian, following the conversion of warrants issued in March 2025. The conversion was executed at Rs 20 per share, which represents a premium over the current market price of Rs 17.6. The company received the final 75% payment totaling Rs 1.13 crore, a significant amount relative to its TTM revenue of Rs 8 crore. Post-allotment, the company's paid-up capital has increased to Rs 14.48 crore.
- Allotment of 7,53,334 equity shares at an issue price of Rs 20 per share (Rs 10 face value + Rs 10 premium)
- Receipt of Rs 1.13 crore representing the balance 75% exercise price from one non-promoter allottee
- Total paid-up equity capital increased to Rs 14,48,39,290 comprising 1,44,83,929 shares
- Remaining outstanding warrants for future conversion stand at 7,80,001 units
- The conversion price of Rs 20 is approximately 13.6% higher than the current market price of Rs 17.6
Venmax Drugs and Pharmaceuticals has approved the allotment of 21,47,665 equity shares following the conversion of warrants by eight non-promoter investors. The conversion occurred at an issue price of Rs 20 per share, which represents a premium over the current market price of Rs 17.6. The company received Rs 3.22 crore as the balance 75% exercise price. This capital infusion is significant, representing approximately 21% of the company's current market capitalization of Rs 15 crore.
- Allotment of 21,47,665 equity shares of face value Rs 10 at a premium of Rs 10 per share
- Receipt of Rs 3,22,14,975 as the balance 75% payment for warrant exercise
- Total paid-up capital increased to Rs 13.73 crore comprising 1,37,30,595 shares
- Conversion price of Rs 20 is a ~13.6% premium to the current market price of Rs 17.6
- 15,33,335 warrants remain outstanding for future conversion out of the original 1,00,25,000 warrants
நிறுவனச் சுயவிவரம்
நிதிச் செயல்திறன்
இந்த நிறுவனத்துக்கான நிதிப் பகுப்பாய்வுத் தரவு இன்னும் கிடைக்கவில்லை.
செயல்பாட்டு உந்துசக்திகள்
இந்த நிறுவனத்திற்கான செயல்பாட்டுப் பகுப்பாய்வுத் தரவு இன்னும் கிடைக்கவில்லை.
வியூக வளர்ச்சி
இந்த நிறுவனத்துக்கான வியூக வளர்ச்சிப் பகுப்பாய்வு இன்னும் கிடைக்கவில்லை.
வெளிப்புறக் காரணிகள்
இந்த நிறுவனத்துக்கு வெளிப்புறக் காரணிகளின் பகுப்பாய்வு இன்னும் கிடைக்கவில்லை.
ஒழுங்குமுறை & நிர்வாகம்
இந்த நிறுவனத்திற்கான ஒழுங்குமுறைப் பகுப்பாய்வு இன்னும் கிடைக்கவில்லை.
அபாயப் பகுப்பாய்வு
இந்நிறுவனத்துக்கான அபாய பகுப்பாய்வு இன்னும் கிடைக்கவில்லை.
